



## Checklist for enrolling a participant in the BSRBR-RA

Please include this form with the documents for each participant you wish to register with the BSRBR-RA

I have given my patient the Participant Information Sheet **and** Transparency Information Sheet and answered any questions

The participant has consented to be involved in the study

Please note: only participants who agree to **all** sections of the consent form can be enrolled in the study. Each box on the consent form should be **initialled** to indicate consent.

I have enclosed the following completed documents:

1. Signed Patient Consent Form (version 9)

2. **Completed\*** Clinical Baseline Form (Clinical Baseline Form V11.2 for patients new to the study or Short Baseline Form V3.1 for re-registering patients to a new cohort)

3. HAQ

4. EQ5D

*\*Please ensure that the baseline form is completed with as much information as possible. If there are important data missing such as biologic therapy, disease severity measures or existing co-morbidities, it may be necessary to exclude these important patients in future BSRBR-RA analyses, thus losing all their information collected to date. Where essential data is missing, the registration documents will be returned to you for completion.*

Please send the registration documentation to the BSRBR-RA study offices:

BSRBR-RA  
Unit 4 Rutherford House  
40 Pencroft Way  
Manchester Science Park  
Manchester  
M15 6SZ

Fax: 0161 2751640



British Society for  
Rheumatology

Rheumatoid Arthritis Register

The participant will be registered and an ID number assigned. You will be sent follow up forms to complete on a six monthly basis for 3 years and then annually thereafter.

**If you have any questions about eligibility, recruitment, follow up or anything else please do not hesitate to contact the project assistant team who will be happy to help**

Tel: +44 (0)161 275 1652/7390

Email: [biologics.register@manchester.ac.uk](mailto:biologics.register@manchester.ac.uk)

Please ensure that a copy of the original MREC approval and subsequent amendment approval letters have been sent to your Trust R & D department.